Associated Papers
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
41386839 (PubMed )
Supplement: mmc5.xlsx › Table_S3
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Shouval R et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2022
34860572 (PubMed )
Supplement: DS_JCO.21.02143.xlsx › Table_S3
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
33630025 (PubMed )
Supplement: jamaoncol-e207987-s004.xlsx › Table
Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G et al.
Molecular Oncology, 2020
32484602 (PubMed )
Supplement: MOL2-14-1640-s002.pdf
Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.
Végran F et al.
Plos One, 2013
Select a paper to view details